Tempest Therapeutics Finalizes Prospectus for Resale of 2.78M Shares, Securing Potential $4M from Warrants

summarizeSummary

Tempest Therapeutics filed a final prospectus for the resale of up to 2.78 million shares by selling stockholders, including an entity linked to the CEO, which also details warrants that could generate approximately $4 million for the company upon exercise.

check_boxKey Events

• Finalizes Resale Offering

  This 424B3 prospectus finalizes the resale of 2,777,781 shares of common stock by selling stockholders, including shares underlying warrants. This follows the S-3 registration statement filed on April 2, 2026.

• Potential Capital Infusion from Warrants

  The company stands to receive approximately $4 million from the cash exercise of Series A and Series B Warrants, which have an exercise price of $2.16 per share, above the current market price of $1.59.

• Significant Dilution Impact

  The resale of 2,777,781 shares represents a potential dilution of approximately 19.4% of the company's outstanding common stock.

• CEO-Affiliated Entity Participation

  Factor Bioscience Inc., an entity where CEO Dr. Matthew Angel is a majority equityholder, participated in the initial private placement, acquiring shares and warrants for over $500,000.

auto_awesomeAnalysis

This 424B3 filing finalizes the terms for the resale of up to 2.78 million shares by selling stockholders, following an S-3 registration statement filed on April 2, 2026. While the company will not receive direct proceeds from the resale of these shares, it stands to gain approximately $4 million from the exercise of associated Series A and Series B Warrants. Notably, these common warrants have an exercise price of $2.16 per share, which is a premium to the current stock price of $1.59, indicating investor confidence in future appreciation. This capital infusion is critical for Tempest Therapeutics, especially given its recent 'going concern' warning disclosed in the March 30, 2026 10-K filing. The participation of Factor Bioscience Inc., an entity where the CEO is a majority equityholder, in the initial private placement further signals internal conviction, despite the dilutive effect of the overall offering.